Affordable Access

Access to the full text

Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist

Authors
  • Pitman, Kathinka E.1
  • Bakke, Kine M.1, 2
  • Kristian, Alexandr3
  • Malinen, Eirik1, 3
  • 1 University of Oslo, P.O. Box 1048 Blindern, Oslo, 0316, Norway , Oslo (Norway)
  • 2 Akershus University Hospital, Lørenskog, Norway , Lørenskog (Norway)
  • 3 Oslo University Hospital, Oslo, Norway , Oslo (Norway)
Type
Published Article
Journal
Cancer Imaging
Publisher
BioMed Central
Publication Date
Dec 19, 2019
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s40644-019-0280-y
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundDynamic contrast enhanced magnetic resonance imaging (DCE-MRI) may be used to depict tumour vascular structure and for therapy response assessment in various tumour sites. The purpose of the current work is to examine whether ultra-early changes in tumour physiology following cytotoxic treatment with doxorubicin and liver X receptor (LXR) agonist GW3965 are detectable by DCE-MRI.Methods36 female, athymic nude foxn1nu mice with bilaterally implanted breast cancer xenografts (17 with ER-positive HBCx34, 19 with triple-negative HBCx39) were randomised in the following treatment groups; control, GW3965 (40 mg/kg p.o.), doxorubicin (8 mg/kg i.v.) and a combination therapy of GW3965 and doxorubicin. DCE-MRI (3D FLASH on a 7 T preclinical scanner) was performed at baseline and one and six days after onset of treatment. Wash-in (30 s p.i.) and wash-out (300 s p.i.) enhancement were quantified from dynamic uptake curves, before voxel-by-voxel fitting to the pharmacokinetic Tofts model and generation of maps for the resulting parameters Ktrans, νe and νB. Treatment effect was evaluated by univariate repeated measures mixed-effects maximum likelihood regression models applied to median tumour data.ResultsWe found no effects of any treatment 24 h post treatment. After 6 days, doxorubicin given as both mono- and combination therapy gave significant increases of ~ 30% in wash-in enhancement (p < 0.011) and Ktrans (p < 0.017), and 40–50% in νB (p < 0.024) for HBCx34, but not for HBCx39. No effects of GW3965 were observed at any time (p > 0.1).ConclusionsTwenty-four h after onset of treatment was too early to evaluate treatment effects by DCE-MRI. Early enhancement and Ktrans were approximately equally sensitive metrics to capture treatment effects six days pt. Pharmacokinetic modelling however allowed us to attribute the observed effect to changes in tumour perfusion rather than increased retention.

Report this publication

Statistics

Seen <100 times